Related Experiment Video
Updated: Apr 23, 2026
07:24
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
1.4K
Additive solution-7 reduces the red blood cell cold storage lesion
Jose A Cancelas1, Larry J Dumont, Lou A Maes
1Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Transfusion
|September 20, 2014
Summary
New additive solution-7 (AS-7) improves red blood cell (RBC) storage, reducing the storage lesion. RBCs stored in AS-7 show better viability and longer shelf life compared to current methods.
Area of Science:
- Transfusion Medicine
- Hematology
- Biochemistry
Background:
- Transfusion of aged red blood cells (RBCs) is linked to adverse outcomes due to the RBC storage lesion.
- Improving RBC storage quality is critical in transfusion medicine.
- Additive Solution-7 (AS-7) is a novel storage solution designed to enhance RBC metabolism.
Purpose of the Study:
- To evaluate the efficacy of AS-7 in preserving RBC quality during extended storage.
- To compare the storage lesion in RBCs stored in AS-7 versus the control solution AS-1.
Main Methods:
- A prospective, randomized, three-center trial was conducted.
- RBCs were stored in AS-7 (n=120) for up to 56 days or in AS-1 (n=60) for 42 days.
- Storage quality, hemolysis, microvesicle shedding, and in vivo recovery were assessed.
Main Results:
- AS-7 significantly reduced hemolysis and microvesicle shedding compared to AS-1 at 42 and 56 days.
- Autologous in vivo recovery of RBCs stored in AS-7 was 88% at 42 days and 82% at 56 days.
- These recovery rates exceed those of RBCs stored in current solutions.
Conclusions:
- Enhanced phosphate content, pH range, and buffering capacity in AS-7 improve RBC storage.
- AS-7 effectively mitigates the long-term RBC storage lesion.
- AS-7 leads to significantly improved in vitro and in vivo RBC viability.
